Alumni Nikhil Tiwari
| Nikhil Tiwari | |
| Occupation | Co-founder and CEO of Frekil |
|---|---|
| Known for | Frekil, intelligence layer for clinical real-world data |
| Education | Indian Institute of Technology Bombay (B.Tech, 2024) |
Nikhil Tiwari is an Indian-American software engineer and entrepreneur. He is the co-founder and CEO of Frekil, a healthcare technology company that builds an intelligence layer over clinical real-world data (RWD) to automate the generation of real-world evidence (RWE) for life sciences and regulatory purposes. Frekil is backed by Y Combinator as part of its Spring 2025 (X25) batch.[1]
Career
Tiwari graduated from the Indian Institute of Technology Bombay with a B.Tech degree in 2024. During his time at IIT Bombay, he led technology initiatives that were used by over 10,000 students within the student body.[2]
Prior to founding Frekil, Tiwari held engineering roles at Stripe, Amazon, and Marsh McLennan, where he worked on infrastructure, distributed systems, performance optimization, and AI/ML infrastructure. He also served as a fractional Chief Product Officer in the health technology space, leading remote development teams focused on telehealth and AI products.
In 2025, Tiwari co-founded Frekil alongside Shivesh Gupta, who serves as co-founder and CTO. The company is headquartered in San Francisco, California. Frekil's platform is designed to convert raw clinical data — including electronic health records (EHR), insurance claims, registries, and proprietary datasets — into regulatory-grade evidence. The platform automates several steps in the real-world evidence pipeline: it maps and standardizes incoming data schemas to the OMOP Common Data Model, generates FDA-aligned study protocols using artificial intelligence, produces transparent and auditable R and Python code for statistical analysis executed in a secure sandbox environment, and outputs submission-ready tables, figures, and listings (TFLs).[3]
The platform's capabilities include target trial emulation, cohort extraction, survival analysis, and sensitivity analyses on treatment sequences. According to user testimonials on the company's website, the platform is used by researchers for tasks such as comparing treatment outcomes, validating prognostic scores, and generating publication-ready statistical outputs with full reproducibility.
Tiwari is a member of Forbes Councils and has published on the topic of transparency in AI within the healthcare sector.
References